Mechanisms of antiplatelet and antithrombotic activity of midazolam in in vitro and in vivo studies

European Journal of Pharmacology

Volumn 487, Issue 1-3, 2004, Pages 159-166

  Hsiao, George ^a   Shen, Ming Yi ^a   Chou, Duen Suey ^a   Chang, Yi ^b   Lee, Lin Wen ^a   Lin, Chien Huang ^a   Sheu, Joen Rong ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cyclic AMP; Midazolam; Na + H+ exchanger; Phospholipase C; Platelet aggregation; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ION; CYCLIC AMP; CYCLIC GMP; HYDROXYL RADICAL; MIDAZOLAM; NITRIC OXIDE; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN P47; THROMBIN;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ELECTRON SPIN RESONANCE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENTERIC VEIN; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; THROMBOCYTE; THROMBOCYTE AGGREGATION;

BLOOD PLATELETS; CYCLIC AMP; CYCLIC GMP; ELECTRON SPIN RESONANCE SPECTROSCOPY; FIBRINOLYTIC AGENTS; FLUORESCEIN; FLUORESCENT DYES; FREE RADICALS; FURA-2; HUMANS; HYDROGEN-ION CONCENTRATION; INOSITOL PHOSPHATES; MICROCIRCULATION; MIDAZOLAM; NITRATES; PHOSPHOLIPIDS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 1642345423     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.01.026     Document Type: Article

References (27)

1. Broekman M.J., Ward J.W., Marcus A.J. Phospholipid metabolism in stimulated human platelet. Changes in phosphatidylinositol, phosphatidic acid, and lysophospholipids. J. Clin. Invest. 66:1980;275-283.
2. Chesney C.M., Pifer D.D., Cagen L.M. Triazolobenzodiazepines competitively inhibit the binding of platelet activating factor to human platelets. Biochem. Biophys. Res. Commun. 144:1987;359-366.
3. Choppin A., Berry C.N. Peripheral benzodiazepine ligands inhibit aggregation and thromboxane synthesis induced by arachidonic acid in rabbit platelet in vitro. Thromb. Res. 78:1995;293-302.
4. Claassen J., Hirsch L.J., Emerson R.G., Mayer S.A. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 43:2002;146-153.
5. + exchanger activity in renal BBMW by stimulation of adenylate cyclase. Am. J. Physiol. 259:1990;F297-F303.
6. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
7. Harper K.W., Collier P.S., Dundee J.W., Elliot P., Halliday N.J. Age and nature of operation influence the pharmacokinetics of midazolam. Br. J. Anaesth. 57:1985;866-871.
8. Horne W.C., Norman N.E., Schwartz D.B., Simons E.R. Changes in cytoplasmic pH and in membrane potential in thrombin-stimulated human platelets. Eur. J. Biochem. 120:1981;295-302.
9. Hsiao G., Shen M.Y., Lin K.H., Chou C.Y., Tzu N.H., Lin C.H., Chou D.S., Chen T.F., Sheu J.R. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur. J. Pharmacol. 465:2003;281-287.
10. Karaseva T.L., Belikova M.V., Pavlovskii V.I., Andronati K.S., Kabanova T.A. In vitro effect of 1,2-dihydro-3H-1,4-benzodiazepine-2-one derivatives on the platelet aggregation and lipid peroxidation in rats. Ukr. Biokhim. Z. 70:1998;81-85. (Russian).
11. Karniguian A., Legrand Y.J., Caen J.P. Prostaglandins: specific inhibition of platelet adhesion to collagen and relationship with cyclic AMP level. Prostaglandins. 23:1982;437-457.
12. +2. J. Clin. Invest. 89:1992;1121-1127.
13. Kirk C.J., Creba J.A., Downes C.P., Michell R.H. Hormone-stimulated metabolism of inositol lipids and its relationship to hepatic receptor function. Biochem. Soc. Trans. 9:1981;377-379.
14. Kornecki E., Ehrlich Y.H., Lenox R.H. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science. 226:1984;1454-1456.
15. Lingjaerde O. Effects of the benzodiazepine receptor ligands midazolam, RO15-1788 and RO 5-4864, alone or in combination, on platelet serotonin uptake. Pharmacopsychiatry. 19:1986;15-18.
16. Murohara T., Parkinson S.J., Waldman S.A., Lefer A.M. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. Arterioscler. Thromb. Vasc. Biol. 15:1995;2068-2075.
17. + exchange via activation of the thrombin receptor. Biochem. J. 297:1994;47-52.
18. Ramoska E.A., Linkenheimer R., Glasgow C. Midazolam use in the emergency department. J. Emerg. Med. 9:1991;247-251.
19. Romstedt K., Huzoor A. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of anti-platelet actions of flurazepam and diazepam. Thromb. Res. 38:1985;361-374.
20. Salvemini D., Botting R. Modulation of platelet function by free radicals and free-radical scavengers. Trends Pharmacol. Sci. 14:1993;36-42.
21. Sheu J.R., Chao S.H., Yen M.H., Huang T.F. In vivo antithrombotic effect of triflavin, an Arg-Gly-Asp containing peptide on platelet plug formation in mesenteric microvessels of mice. Thromb. Haemost. 72:1994;617-621.
22. Sheu J.R., Hung W.C., Kan Y.C., Lee Y.M., Yen M.H. Mechanisms involved in the antiplatelet activity of Escherichia coli lipopolysaccharide in human platelets. Br. J. Haematol. 103:1998;29-38.
23. Sheu J.R., Hung W.C., Wu C.H., Ma M.C., Kan Y.C., Lin C.H., Lin M.S., Luk H.N., Yen M.H. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. Circulation. 99:1999;3056-3062.
24. Sheu J.R., Lee C.R., Lin C.H., Hsiao G., Ko W.C., Chen Y.C., Yen M.H. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. Thromb. Haemost. 83:2000;777-784.
25. Sheu J.R., Hsiao G., Luk H.N., Chen Y.W., Chen T.L., Lee L.W., Lin C.H., Chou D.S. Mechanisms involved in the antiplatelet activity of midazolam in human platelets. Anesthesiology. 96:2002;651-658.
26. +2 concentrations in essential hypertension. Hypertension. 22:1993;853-862.
27. 2+ in platelets is controlled by cyclic AMP: antagonism between stimulators and inhibitors of adenylate cyclase. Biochem. Biophys. Res. Commun. 120:1984;579-585.